These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 6615690

  • 1. The contribution of genetically determined oxidation status to inter-individual variation in phenacetin disposition.
    Devonshire HW, Kong I, Cooper M, Sloan TP, Idle JR, Smith RL.
    Br J Clin Pharmacol; 1983 Aug; 16(2):157-66. PubMed ID: 6615690
    [Abstract] [Full Text] [Related]

  • 2. Metabolism of paracetamol and phenacetin in relation to debrisoquine oxidation phenotype.
    Veronese ME, McLean S.
    Eur J Clin Pharmacol; 1991 Aug; 40(6):547-52. PubMed ID: 1884734
    [Abstract] [Full Text] [Related]

  • 3. Polymorphism of carbon oxidation of drugs and clinical implications.
    Sloan TP, Mahgoub A, Lancaster R, Idle JR, Smith RL.
    Br Med J; 1978 Sep 02; 2(6138):655-7. PubMed ID: 151576
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Metabolism of methoxyphenamine in extensive and poor metabolizers of debrisoquin.
    Roy SD, Hawes EM, McKay G, Korchinski ED, Midha KK.
    Clin Pharmacol Ther; 1985 Aug 02; 38(2):128-33. PubMed ID: 4017414
    [Abstract] [Full Text] [Related]

  • 10. Influence of debrisoquine hydroxylation phenotype on the pharmacokinetics of mexiletine.
    Lledó P, Abrams SM, Johnston A, Patel M, Pearson RM, Turner P.
    Eur J Clin Pharmacol; 1993 Aug 02; 44(1):63-7. PubMed ID: 8436157
    [Abstract] [Full Text] [Related]

  • 11. Polymorphic drug oxidation in humans.
    Eichelbaum M.
    Fed Proc; 1984 May 15; 43(8):2298-302. PubMed ID: 6714436
    [Abstract] [Full Text] [Related]

  • 12. Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.
    Speirs CJ, Murray S, Boobis AR, Seddon CE, Davies DS.
    Br J Clin Pharmacol; 1986 Dec 15; 22(6):739-43. PubMed ID: 3567021
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The relationship between debrisoquine oxidation phenotype and the pharmacokinetics of chlorpropamide.
    Kallio J, Huupponen R, Pyykkö K.
    Eur J Clin Pharmacol; 1990 Dec 15; 39(1):93-5. PubMed ID: 2276394
    [Abstract] [Full Text] [Related]

  • 17. Debrisoquine oxidation in a Finnish population: the effect of oral contraceptives on the metabolic ratio.
    Kallio J, Lindberg R, Huupponen R, Iisalo E.
    Br J Clin Pharmacol; 1988 Dec 15; 26(6):791-5. PubMed ID: 3242585
    [Abstract] [Full Text] [Related]

  • 18. Enantioselectivity of 4-hydroxylation in extensive and poor metabolizers of debrisoquine.
    Eichelbaum M, Bertilsson L, Küpfer A, Steiner E, Meese CO.
    Br J Clin Pharmacol; 1988 Apr 15; 25(4):505-8. PubMed ID: 3382592
    [Abstract] [Full Text] [Related]

  • 19. Electrochemical oxidation by square-wave potential pulses in the imitation of phenacetin to acetaminophen biotransformation.
    Nouri-Nigjeh E, Bischoff R, Bruins AP, Permentier HP.
    Analyst; 2011 Dec 07; 136(23):5064-7. PubMed ID: 21984979
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.